Groups Partner to Increase Diversity in Cancer Clinical Trials
The goal is to increase diversity in cancer clinical trials
Despite the well-known importance of clinical trial results, racial and ethnic minority populations continue to be underrepresented in cancer treatment trials when compared with the overall population of patients with cancer.
The American Society of Clinical Oncology (ASCO) and Association of Community Cancer Centers (ACCC) are teaming up on an initiative to encourage broader participation in cancer treatment trials to better reflect the diversity of people who are at risk of developing the disease. The groups recently announced a joint call to action to the cancer community to submit novel strategies and practical solutions in a Request for Ideas.
ACCC President Randall A. Oyer, M.D., and ASCO President Lori J. Pierce, M.D., have complementary overarching goals that spurred the collaboration. Oyer is focused on using community oncology to close the known gap in research and diverse patient populations, and Pierce is committed to ensuring all patients have access to equitable cancer care.
Please select this link to read the complete article from Associations Now.